{"contentid": 488001, "importid": NaN, "name": "Canakinumab results disappoint but other studies go on", "introduction": "Novartis has announced that the Phase III CANOPY-2 study evaluating canakinumab in combination with the chemotherapy agent docetaxel, did not meet its primary endpoint of overall survival.", "content": "<p>Novartis (NOVN: VX) has announced that the Phase III CANOPY-2 study evaluating canakinumab in combination with the chemotherapy agent docetaxel, did not meet its primary endpoint of overall survival (OS).</p>\n<p>The trial was conducted among 237 adults with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy.</p>\n<p>Canakinumab is a human monoclonal antibody that binds with high affinity and selectivity to human interleukin-1beta (IL-1&beta;) and neutralizes IL-1&beta; activity by blocking its interaction with its receptors. It&nbsp;is already marketed as an inflammatory disease treatment under the brand name Ilaris, and Novartis made an earlier unsuccessful attempt to expand its use to the cardiovascular setting.</p>\n<p>John Tsai, head of global drug development and chief medical officer at the Swiss pharma company, said: &ldquo;While results from the CANOPY-2 trial are not what we hoped for in patients with advanced or metastatic NSCLC who have been treated with other lines of therapy, these data give us valuable insights into IL-1&beta; inhibition.</p>\n<p>&ldquo;Ongoing Phase III studies in NSCLC continue, evaluating canakinumab in earlier treatment settings.&rdquo;</p>", "date": "2021-03-10 15:40:00", "meta_title": NaN, "meta_keywords": "canakinumab, CANOPY-, Novartis, chemotherapy, Phase, evaluating, results, disappoint, studies, announced, primary, survival, endpoint, agent, meet, study", "meta_description": "Novartis has announced that the Phase III CANOPY-2 study evaluating canakinumab in combination with the chemotherapy agent docetaxel, did not meet its primary e", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-10 15:10:00", "updated": "2021-03-10 15:41:13", "access": NaN, "url": "https://www.thepharmaletter.com/article/canakinumab-results-disappoint-but-other-studies-go-on", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "2020_novartis_big.jpg", "image2id": "2020_novartis_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Oncology", "topic_tag": "Drug Trial, Research", "geography_tag": "Switzerland", "company_tag": "Novartis", "drug_tag": "canakinumab", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-10 15:40:00"}